Literature DB >> 17063195

An Auckland regional audit of the nurse-led rheumatic fever secondary prophylaxis programme.

Sarah Grayson1, Margaret Horsburgh, Diana Lennon.   

Abstract

BACKGROUND: Rheumatic fever with ensuing rheumatic heart disease is considered to be a preventable chronic disease. AIM: To assess the compliance rates with the rheumatic fever secondary prophylaxis programme established through the Auckland Rheumatic Fever Register and managed by community nursing services in Auckland, New Zealand.
METHODS: An audit of the 1998 and 2000 Auckland Rheumatic Fever Register data was undertaken to establish the compliance rates of patients with the rheumatic fever secondary prophylaxis programme. The sample included all patients on the Auckland Rheumatic Fever Register during this time.
RESULTS: Results showed compliance rates across the three Auckland DHBs ranging from 79.9% to 100% for individual community nursing offices.
CONCLUSION: A community-based nurse-led secondary prophylaxis programme for Rheumatic Fever heart disease is able to deliver excellent patient compliance levels. Secondary prophylaxis is the WHO-recommended cost effective first step to Rheumatic Fever/Rheumatic Heart Disease control. Community health workers have a key role to play in facilitating this compliance.

Entities:  

Mesh:

Year:  2006        PMID: 17063195

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  8 in total

1.  Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever, Jamaica.

Authors:  Sheron Boswell Thompson; Cerese Hepburn Brown; Ann Marie Edwards; Jascinth L M Lindo
Journal:  Pathog Glob Health       Date:  2014-08-11       Impact factor: 2.894

2.  No demonstrable effect of benzathine penicillin on recurrence of rheumatic Fever in pacific island population.

Authors:  Michael D Seckeler; Tracey R Hoke; Matthew J Gurka; Leslie L Barton
Journal:  Pediatr Cardiol       Date:  2010-04-22       Impact factor: 1.655

3.  Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.

Authors:  Rosemary Wyber; Ben J Boyd; Samantha Colquhoun; Bart J Currie; Mark Engel; Joseph Kado; Ganesan Karthikeyan; Mark Sullivan; Anita Saxena; Meru Sheel; Andrew Steer; Joseph Mucumbitsi; Liesl Zühlke; Jonathan Carapetis
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

4.  Failure of oral penicillin as secondary prophylaxis for rheumatic heart disease: a lesson from a low-prevalence rheumatic fever region.

Authors:  S M McGlacken-Byrne; H M Parry; P F Currie; N J Wilson
Journal:  BMJ Case Rep       Date:  2015-11-03

5.  Adherence to Benzathine Penicillin G Secondary Prophylaxis and Its Determinants in Patients with Rheumatic Heart Disease at a Cardiac Center of an Ethiopian Tertiary Care Teaching Hospital.

Authors:  Kajela Kibirat Mekonen; Malede Berihun Yismaw; Alfoalem Araba Abiye; Tamrat Assefa Tadesse
Journal:  Patient Prefer Adherence       Date:  2020-02-19       Impact factor: 2.711

6.  Sharing success - understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease.

Authors:  Jennifer Chamberlain-Salaun; Jane Mills; Priya M Kevat; Marc G W Rémond; Graeme P Maguire
Journal:  BMC Cardiovasc Disord       Date:  2016-08-31       Impact factor: 2.298

7.  Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review.

Authors:  Priya M Kevat; Benjamin M Reeves; Alan R Ruben; Ronny Gunnarsson
Journal:  Curr Cardiol Rev       Date:  2017

8.  The personal and clinical impact of screen-detected maternal rheumatic heart disease in Uganda: a prospective follow up study.

Authors:  Sonia Voleti; Emmy Okello; Meghna Murali; Rachel Sarnacki; Albert Majwala; Renny Ssembatya; Olivia Bakka; Henriator Namisanvu; Angela Njeri; Alphonsus Matovu; Kristen DeStigter; Craig Sable; Andrea Beaton
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-09       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.